Twist BioscienceTWST
Recorded

Twist Bioscience Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matt StantonSVP of Equity Research

All right, great. Thanks, everyone. I am Matt Stanton on the Life Science Tools & Diagnostics team here at Jefferies. Happy to have Twist with us at the conference this year. Joining us from the company, we have Emily and Adam. Thanks both of you for being here this afternoon. Emily, I thought it would be helpful to kick off for those that are newer to the Twist story, maybe just talk a little bit about who Twist is, some of the differentiation in your technology, writing DNA on a silicon chip, why that matters, and then also maybe talk to the evolution of the company. Started gene synthesis, you have added a number of markets, NGS, antibody discovery, protein, diagnostics, and how that evolution has expanded the TAM over time as well.

Emily LeproustCEO

Yeah, thank you for the invitation, and it is our first time at Jefferies. Hopefully we get invited again. We started Twist in 2013. The idea was to miniaturize the chemistry of writing DNA. I am a DNA chemist. Our CTO is a DNA chemist, our CEO is a DNA chemist, so we are very much in DNA chemistry. The chemistry of writing DNA is well-known, four letters, A, C, G, T, and everybody uses a 96-well plate. It is a piece of plastic the size of an iPhone, and people traditionally make 96 pieces of DNA or oligos on that format. We miniaturized the chemistry, and now we, in the same footprint, we can make 1 million pieces of DNA, 1 million oligos. So gave us massive throughput, much lower cost.

Emily LeproustCEO

I will spare you the details on fluid dynamics, but it also gave us better quality, enabled us over the years do the direct synthesis of longer pieces of DNA than the competition. So that is the technology base, platform for the company. Very quickly, or actually from the beginning, we realized that we will have a foundry business model. The fixed cost will be substantial, but the variable cost, because we miniaturized everything, will be very small. We built a strategy where we will bring volumes on the chip. For a foundry model, volumes is your friend. Again, the variable costs are very small. To get to bring volume, we developed a new product introduction engine where we will develop newer and newer flavors of DNA to be able to serve more applications.

Emily LeproustCEO

In 2021, for instance, we were serving a SAM, serviceable available market, of $2 billion. Right now, 2026, we are serving a SAM of $7 billion, and we have line of sight to get to $13 billion. From that expansion into flavors of DNA, we also expanded the different applications that we will support. The two big ones are the diagnostic field, where we enable the library prep and the enrichment prior to sequencing, in areas such mostly in cancer diagnostic, as well as a smaller participation in rare disease. So that is one big application. Another big application for us is in therapeutics or drug discovery. Drug discovery is a big market, but was very, very fragmented. Very few company cracked ever the $50 million revenue per year.

Emily LeproustCEO

If you ask five drug discoverers how to discover drugs, you will get six answers. Everybody wanted to do things differently. Our idea was to enable all the workflows and do it in a way that was best in class. That has been a very, very successful strategy. Lately, a new way of doing discovery has emerged, and that is AI-enabled drug discovery. There, in AI drug discovery, our customers use the engineering principle of design, build, test, learn. The learn and the design is a dry lab effort, and then the build and testing, that is a wet lab effort. Our customers do the compute for learning and design on their servers, and then they outsource to us the building and the testing. That has been a great source of growth for us.

Emily LeproustCEO

I am sure we will come back to that, but we had $21 million of revenue in 2025, which ended in September, the September month for us. In 2026, we grew 175% to $59 million. So great growth. We have guided $100 million of AI drug discovery revenue in 2027. Overall, for the company, last year, we got to $459 million, and we guided for next year, $550 million-$560 million. We have been on the march to deliver quarter after quarter after quarter, and year after year, revenue growth. The last quarter was a very important milestone for Twist, where for the first time, we got to adjusted EBITDA break-even.

Emily LeproustCEO

Again, the idea of Twist is a technology platform of silicon chip, building a new product introduction engine on top of it, layered with application support in key areas of life science, and then delivering financial performance that are, we think, best in class compared to our peers.

Matt StantonSVP of Equity Research

All right. Great. Thanks. Maybe Adam, just on the 2027 guide, I think you talked about low 20s growth on a 20% comp, kind of rarefied air. I think a lot of focus is on just potential upside drivers, given in 2026, I think you guys ended up beating the initial guide by 8%, right? Obviously, AI is in focus, and we will get to that, but any other kind of upside drivers you talk about? Do you have a healthy new product cadence? Maybe academic government comes back, you have some capacity adds coming online. How do we just think about kind of guidance philosophy on tough comps and then some of the potential upside drivers moving through the year?

Adam LaponisCFO

Matt, thanks for the question. Great to be here, everyone. When we look at the business, we are always looking for new areas and opportunities of growth, and we see that diversity as being one of our strengths. For us, when we look at 2027, the guidance is based on the same principles we've guided to in the past, and that is understanding the demand that's in front of us that we have a high degree of confidence in. We're as equally excited about the opportunity for upside in areas like NGS and MRD expansion. We saw over 20% growth in Q4 in our academics. We know that funding has been under pressure, but we believe we're taking meaningful market share given our unique value proposition in that space.

Adam LaponisCFO

Of course, we'd be reluctant without saying AI-enabled drug discovery is a huge potential opportunity, an area for upside, but also an area where we're continuously investing into. Part of what we're doing in 2027 is adding capacity to ensure we can continue that accelerated rate of expansion.

Matt StantonSVP of Equity Research

Okay. Maybe just real quick on academic government, it used to be a big focus, now it never comes up, but it's still low double-digit percent of your mix. Like you said, you've seen really nice growth despite kind of a choppy end market. If we do see academic government markets come back a bit more meaningfully in the U.S., is there further upside? How should we think about kind of those share gains you talked about, and then just a potential broader recovery on the horizon here?

Adam LaponisCFO

Yeah. No, I think that one of the most exciting parts about Twist is, in any market, we find a way to grow. As part of that is the value proposition of high quality, high speed, best-in-class pricing too. You have all three together, it's a winning proposition in a strong economy, but it's even stronger winning proposition in a tough market. When you're in a tough market as a customer, they're looking for more value, and they're considering switching suppliers. That's our opportunity to take share, which we believe we've done. Again, if the market rebounds, we haven't built that into our guidance, but if that happens, that is an area of opportunity for continued upside is that we grow with the customers we've now acquired.

Matt StantonSVP of Equity Research

Okay. Shifting gears to AI drug discovery. You talked about orders accelerating, I think, throughout the year in 2026. That kind of is informing this triple-digit growth you are talking about in scope for 2027. Maybe just unpack a little bit more how orders evolved over the course of 2026, where you saw kind of strength, and what is kind of underpinning that acceleration you guys talked about throughout the year.

Emily LeproustCEO

Yeah. For us, just to maybe set the stage of how we are looking at our customers, we have been in AI-enabled drug discovery since the first half of calendar 2025. Now we have multiple cohorts. When it started, we had just a few customers. One in particular was a top five pharma, and it was always a native AI-enabled drug discovery company. They kind of set the stage for the phases that are being reproduced again and again as we add new customers. There are mostly three phases. The first phase is a pilot. Very small dollar orders, $10,000, $100,000, where they send us sequences, targets, and a list of assays that they want run. If it is a cell-free workflow, we ship the data in 10 days. If it is a cell-based workflow, it is in 20-ish days.

Emily LeproustCEO

After that pilot, they come back in a second phase where they will do model building. There, the numbers of sequences that they want data for just increases tremendously. It is a very lumpy time where now they want thousands, tens of thousands of sequences, again, delivered in 10 or 20 days. When we ship the data, we have to wait because they need quite a bit of time to digest that data. Then they enter phase three, which is for us, is production of drug discovery. At that point, they are done with model building, and then they go into the turning of the crank where they declare a target with them. We do a drug discovery campaign where there is discovery optimization cycles. That ends for that target, and it moves on to another target.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day